155960-94-4

Basic information

• Product Name: ethyl 4-chloroquinazoline-6-carboxylate
• Synonyms: ethyl 4-chloroquinazoline-6-carboxylate;6-Quinazolinecarboxylic acid, 4-chloro-, ethyl ester
• CAS NO: 155960-94-4
• Molecular Formula: C₁₁H₉ClN₂O₂
• Molecular Weight: 236.65436
• Product Categories: CHIRAL CHEMICALS
• Mol File: 155960-94-4.mol

Chemical Properties

• Boiling Point: 366.548 °C at 760 mmHg
• Flash Point: 175.482 °C
• Appearance: /
• Density: 1.342 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.615
• PKA: 0.11±0.30(Predicted)
• CAS DataBase Reference: ethyl 4-chloroquinazoline-6-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-chloroquinazoline-6-carboxylate(155960-94-4)
• EPA Substance Registry System: ethyl 4-chloroquinazoline-6-carboxylate(155960-94-4)

Safety Data

• Hazardous Substances Data: 155960-94-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 4-chloroquinazoline-6-carboxylate is used as an intermediate in the synthesis of various pharmaceuticals for its potential therapeutic properties. It serves as a key building block in the production of drugs and related compounds, contributing to the development of new medications.
Used in Agrochemical Industry:
Ethyl 4-chloroquinazoline-6-carboxylate is also used as an intermediate in the synthesis of agrochemicals, playing a crucial role in the development of pesticides and other agricultural products. Its potential biological activities make it a valuable component in creating effective solutions for crop protection and management.

InChI:InChI=1/C11H9ClN2O2/c1-2-16-11(15)7-3-4-9-8(5-7)10(12)14-6-13-9/h3-6H,2H2,1H3

Downstream Products

• 1374764-25-6 C₁₈H₁₆BrN₃O₃ 
• 150450-64-9 4-(3,4-Methylenedioxybenzyl)amino-6-ethoxycarbonylquinazoline 

Relevant articles and documents

Intramolecular Ring-Opening of Oxetanes: Access to Functionalised Hydroxymethyl 2,3-Dihydroimidazo[1,2- c ]quinazolines

An intramolecular oxetane ring-opening was developed, affording novel 2-(hydroxymethyl)-2,3-dihydroimidazo[1,2- c ]quinazolines from N -(3-methyloxetan-3-yl)quinazolin-4-amines under mild conditions. The resulting medicinally relevant tricyclic scaffolds were synthesised in good yields with diverse substituents. Moreover, reaction optimisation led to the development of a one-pot procedure.

NOVEL ANTIMALARIA AGENT CONTAINING HETEROCYCLIC COMPOUND

Disclosed is an antimalarial agent containing a compound represented by the formula: [wherein A1 represents a 3-pyridyl group that may have a substituent, a 6-quinolyl group that may have a substituent, or the like; X1 represents a group represented by the formula -C(=O)-NH- or the like; E represents a furyl group, a thienyl group or a phenyl group; with the proviso that A1 may have one to three substituents, and E has one of two substituents] or a salt thereof or hydrates thereof.

NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND

The present invention provides an antifungal agent represented by the formula: [wherein A1 represents a 3-pyridyl group which may have a substituent, a quinolyl group which may have a substituent, or the like; X1 represents a group represented by the formula -NH-C(=O)-, a group represented by the formula -C(=O)-NH-, or the like; E represents a furyl group, a thienyl group, a pyrrolyl group, a phenyl group, a pyridyl group, a tetrazolyl group, a thiazolyl group or a pyrazolyl group; with the proviso that A1 may have 1 to 3 substituents, and E has one or two substituents].

Cyclic GMP Phosphodiesterase Inhibitors. 2. Requirement of 6-Substitution of Quinazoline Derivatives for Potent and Selective Inhibitory Activity

We synthesized various 4-amino>quinazolines substituted at the 5- to 8-positions and evaluated their inhibitory activities toward cyclic GMP phosphodiesterase (cGMP-PDE) from porcine aorta.Monosubstitution at the 6-position was essential for the inhibitory activity, and the preferred substituents were compact and hydrophobic: methoxy (3b, IC50 = 0.23 μM), methyl (3c, 0.10 μM), chloro (3d, 0.019 μM), thiomethyl (3f, 0.031 μM), and cyano (3p, 0.090 μM) groups.Compounds 3b-d, f, p lacked inhibitory activity toward other PDE isozymes (all IC50 values > 100 μM), and their relaxing activities in porcine coronary arteries were well correlated with the inhibitory activities toward cGMP-PDE (r = 0.88, p 0.05).One of these compounds, 3b, elevated the intracellular cGMP level in isolated porcine coronary arteries without causing any change in the cAMP level.We consider that this series of compounds dilates coronary arteries via potent and specific inhibition of cGMP-PDE.